SCO 5-6, Zirakpur-Panchkula-Kalka Hwy, near Hotel Sunpark, Wadhawa Nagar, Dhakoli, Zirakpur, Punjab 140603

Gliclazide Me ormin 80mg 500mg Tablet

Gliclazide Me ormin 80mg 500mg Tablet - Manufacturers & Suppliers - Third Party Contract Manufacturing - PCD Pharma Franchise

Gliclazide Me  ormin 80mg 500mg Tablet

Composition : Z-GLIC M

Packing : 10x10

Price : Rs. 850

Please Contact Us

Z glic M tablet is a combination of Gliclazide 80 mg+ Metformin 500 mg. Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release.
Metformin is belongs to biguanide classification of drugs.  It lowers glucose production in the liver, delays its absorption from intestines and increases the body's sensitivity to insulin. This combination helps in maintaining both fasting and post meal sugar levels. Together, they provide better control of blood sugar.

• Treatment of NIDDM
• Type 2 Diabetes Mellitus
  Dosage : As directed by Physician
  Mechanism of Action
• Gliclazide
Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. 
• Metformin
Metformin inhibits mitochondrial complex I activity responsible for its potent ant diabetic effect. It decreases gluconeogenesis in liver and also decreases the intestinal absorption of glucose. It also improves the sensitivity of insulin.
Rapidly and well absorbed but may have wide inter- and intra-individual variability. Peak plasma concentrations occur within 4-6 hours of oral administration.

94%, highly bound to plasma proteins

Metabolites and conjugates are eliminated primarily by the kidneys (60-70%) and also in the feces (10-20%).

In fasting condition of the patients, the drug bioavailability is about 50% to 60%. Food decreases the absorption of drug.
The volume of distribution is 654±358 L. It rarely bonds to plasma protein. It does not follow hepatic metabolism.
It is excreted in unchanged form in urine.
• Pregnant and lactation
• severe kidney disease; or.
• metabolic acidosis or diabetic ketoacidosis (call your doctor for treatment).
• Hypoglycemia 
• Taste change
• Nausea
• Diarrhea
• Stomach pain
• Headache
• Upper respiratory tract infection